Biocept Inc (NASDAQ:BIOC)’s share price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.07 and traded as high as $1.11. Biocept shares last traded at $1.10, with a volume of 6,975 shares traded.
Several research analysts recently weighed in on BIOC shares. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Biocept in a research report on Thursday, May 9th. ValuEngine upgraded Biocept from a “hold” rating to a “buy” rating in a research report on Friday, March 1st.
The company has a quick ratio of 2.63, a current ratio of 2.72 and a debt-to-equity ratio of 0.10. The business has a 50 day simple moving average of $1.07. The stock has a market cap of $21.89 million, a P/E ratio of -0.12 and a beta of 2.17.
Biocept (NASDAQ:BIOC) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.61) EPS for the quarter. Biocept had a negative return on equity of 338.61% and a negative net margin of 695.85%. The firm had revenue of $1.02 million for the quarter.
An institutional investor recently raised its position in Biocept stock. Dimensional Fund Advisors LP grew its position in shares of Biocept Inc (NASDAQ:BIOC) by 180.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,500 shares of the medical research company’s stock after purchasing an additional 71,055 shares during the period. Dimensional Fund Advisors LP owned approximately 4.86% of Biocept worth $95,000 as of its most recent SEC filing. 2.34% of the stock is owned by hedge funds and other institutional investors.
Biocept Company Profile (NASDAQ:BIOC)
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
See Also: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.